SG Americas Securities LLC grew its holdings in Revvity, Inc. (NYSE:RVTY – Free Report) by 148.3% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 50,014 shares of the company’s stock after buying an additional 29,870 shares during the period. SG Americas Securities LLC’s holdings in Revvity were worth $6,389,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also made changes to their positions in RVTY. Parallel Advisors LLC acquired a new position in shares of Revvity during the fourth quarter worth about $47,000. CIBC Asset Management Inc acquired a new position in shares of Revvity during the fourth quarter worth about $1,869,000. Rafferty Asset Management LLC acquired a new position in shares of Revvity during the fourth quarter worth about $1,373,000. Royal London Asset Management Ltd. acquired a new position in Revvity during the fourth quarter worth about $5,013,000. Finally, Tower Research Capital LLC TRC acquired a new position in Revvity during the fourth quarter worth about $1,820,000. 86.65% of the stock is owned by hedge funds and other institutional investors.
Revvity Stock Performance
Shares of RVTY stock opened at $123.96 on Friday. The company’s fifty day simple moving average is $121.74 and its 200-day simple moving average is $111.84. The company has a market cap of $15.30 billion, a PE ratio of 102.45, a P/E/G ratio of 2.90 and a beta of 1.05. Revvity, Inc. has a 52 week low of $79.50 and a 52 week high of $128.15. The company has a current ratio of 2.27, a quick ratio of 1.98 and a debt-to-equity ratio of 0.40.
Revvity Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 8th. Stockholders of record on Friday, October 18th will be paid a $0.07 dividend. The ex-dividend date is Friday, October 18th. This represents a $0.28 annualized dividend and a dividend yield of 0.23%. Revvity’s dividend payout ratio is currently 23.14%.
Analysts Set New Price Targets
Several research analysts have weighed in on the stock. Bank of America upped their target price on shares of Revvity from $118.00 to $127.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 30th. Leerink Partnrs upgraded shares of Revvity to a “strong-buy” rating in a research report on Monday, July 8th. JPMorgan Chase & Co. increased their price target on shares of Revvity from $105.00 to $120.00 and gave the company a “neutral” rating in a research report on Tuesday, July 30th. Barclays increased their price target on shares of Revvity from $115.00 to $125.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 30th. Finally, Wells Fargo & Company assumed coverage on shares of Revvity in a research report on Tuesday, August 27th. They issued an “equal weight” rating and a $130.00 price target on the stock. Eight equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $125.53.
Check Out Our Latest Stock Analysis on RVTY
Insider Transactions at Revvity
In other Revvity news, insider Joel S. Goldberg sold 3,500 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $117.86, for a total value of $412,510.00. Following the transaction, the insider now owns 33,400 shares in the company, valued at approximately $3,936,524. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.60% of the company’s stock.
Revvity Company Profile
Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
Featured Articles
- Five stocks we like better than Revvity
- What Are Growth Stocks and Investing in Them
- 3 Key Stocks to Ride China’s Stimulus-Driven Growth
- About the Markup Calculator
- 3 Dividend Growth Stocks Set to Supercharge Your Portfolio
- What is the FTSE 100 index?
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
Want to see what other hedge funds are holding RVTY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revvity, Inc. (NYSE:RVTY – Free Report).
Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.